Loading
Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement, Second Edition

Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement, Second Edition

SKU:10071820-0003
Jürgen Meier, Oswin Ridderbusch
For general delivery times, please see our shipping policy
Price:
$195.00
Product Line
Kluwer Law International
ISBN-13
9789403536262
Availability
Ships in 5-7 Business Days
Last Updated
2023-08-15

Overview

AIPPI Law Series


Antibodies have revolutionized medicine and biotechnology, and have become indispensable tools in therapy, diagnostics, analytics, and research. Therapeutic antibodies, for example, have become firmly established in the ranks of blockbuster drugs, currently accounting for about half of the top 10 best-selling medicines. At the same time, a body of case law dealing specifically with the patentability of antibody-related inventions and the enforcement of antibody patents has emerged in major jurisdictions. The, at times, significant divergences between different jurisdictions have been compounded by recent decisions in the United States, which have severely curtailed the possibilities to obtain broad antibody patents. It is therefore essential to understand how antibody inventions are assessed in different jurisdictions in order to secure an optimal patent protection and to successfully enforce such patents.


Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement, Second Edition provides practitioners with a comprehensive resource elucidating all aspects of the patenting of antibodies from initial drafting and prosecution to enforcement, using a country-by-country format. The updated and expanded Second Edition covers more than 30 of the most important IP jurisdictions worldwide – i.e., the European Patent Office, Belgium, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, the Netherlands, Poland, Spain, Sweden, Switzerland, the United Kingdom, the United States of America, Canada, Mexico, the Andean Community (Bolivia, Colombia, Ecuador, and Peru), Argentina, Brazil, Chile, China, India, Israel, Japan, Singapore, South Korea, Taiwan, Australia, and New Zealand. The 49 contributors to this book, all distinguished experts in this field, provide clear and practice-oriented advice on a range of topics including:


  • Which types of antibody inventions are patent-eligible?
  • Which types of functional and structural features are accepted for claiming antibodies?
  • What needs to be considered when defining antibodies in terms of their antigen, target affinity, binding specificity, epitope, competitive binding and other characteristics in relation to reference antibodies, as well as their effects on the target?
  • Which pitfalls must be avoided when defining amino acid sequences, chemical modifications or glycosylation patterns, and when relying on cell line deposits?
  • Which breadth of claims is accepted for antibody inventions, and what experimental support is required?
  • Which specific medical applications of antibodies can be claimed?
  • How is inventive step assessed in the specific case of antibody inventions?
  • What has to be considered when enforcing antibody patents, including in relation to biosimilars as well as the doctrine of equivalence?

All chapters follow the same structure, which makes this book easily accessible and allows a direct comparison between different jurisdictions. Practitioners will find the much-needed tools and guidance to secure the best possible patent protection for antibody inventions in more than 30 of the most important jurisdictions worldwide.


This book is the fifth volume in the AIPPI Law Series which has been established together with the International Association for the Protection of Intellectual Property (AIPPI), a non-affiliated, non-profit organization dedicated to improving and promoting the protection of intellectual property at both national and international levels.

Table Of Contents

About the Editors


About the Contributors


Foreword

Shoichi Okuyama, President of AIPPI


Acknowledgments

Introduction

Jürgen Meier & Oswin Ridderbusch


Chapter 1 European Patent Office

Jürgen Meier, Oswin Ridderbusch & Hans-Rainer Jaenichen


Chapter 2 Belgium

Koen Vanhalst


Chapter 3 Denmark

Jan Mondrup Pedersen & Jakob Schwalbe Lohmann


Chapter 4 Finland

Krister Karlsson


Chapter 5 France

Cyra Nargolwalla & Isabelle Labarre


Chapter 6 Germany

Oswin Ridderbusch


Chapter 7 Hungary

Adam Svingor


Chapter 8 Ireland

Donal M. Kelly


Chapter 9 Italy

Elisa Turri & Olga Capasso


Chapter 10 The Netherlands

Martin Klok


Chapter 11 Poland

Marta Kawczynska


Chapter 12 Spain

Juan Arias


Chapter 13 Sweden

Niklas Mattsson


Chapter 14 Switzerland

Philipp Marchand


Chapter 15 United Kingdom

Daniel Lim, Kate Taylor & Claire Baldock


Chapter 16 United States of America

John C. Todaro & Michele M. Wales


Chapter 17 Canada

Graeme Boocock & Charles A. Boulakia


Chapter 18 Mexico

Héctor E. Chagoya-Cortes & Israel Jiménez


Chapter 19 Andean Community: Bolivia, Colombia, Ecuador, and Peru

Andres Rincon, Carolina Vargas & Sergio Arboleda


Chapter 20 Argentina

Martin Bensadon & Cristian D. Bittel


Chapter 21 Brazil

Maria Carmen de Souza Brito & Pedro Henrique Borges de Figueiredo


Chapter 22 Chile

Rodrigo Marré Grez & Allison Ortega del Valle


Chapter 23 China

Gesheng Huang


Chapter 24 India

Mamta Rani Jha


Chapter 25 Israel

David Gilat & Mirit Lotan


Chapter 26 Japan

Takashi Fujita & Osamu Yamamoto


Chapter 27 Singapore

Kian Hoe Khoo


Chapter 28 South Korea

Min Son


Chapter 29 Taiwan

Paul C.C. Chen, Yih-Lin Chung, Arpita Dutta & Wei-Ting Liao


Chapter 30 Australia and New Zealand

Michael Christie


Table of Cases

Loading
Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement, Second Edition | Wolters Kluwer Legal & Regulatory